Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Obstructive Lung Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 49 articles:
HTML format



Single Articles


    September 2020
  1. SUNYER J, Anto JM
    Asthma exacerbations, air pollution, and allergens.
    Lancet. 2020;396:753.
    PubMed    


  2. BURNEY P, Amaral AFS
    Asthma exacerbations, air pollution, and allergens - Authors' reply.
    Lancet. 2020;396:753-754.
    PubMed    


  3. VON MUTIUS E, Smits HH
    Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention.
    Lancet. 2020 Sep 7. pii: S0140-6736(20)31861.
    PubMed     Abstract available


    August 2020
  4. POSCHENRIEDER F, Rotter M, Gschwendtner A, Hamer OW, et al
    E-cigarette-induced lung disease: from acute to chronic.
    Lancet. 2020;396:564.
    PubMed    


  5. LANGAN SM, Irvine AD, Weidinger S
    Atopic dermatitis.
    Lancet. 2020;396:345-360.
    PubMed     Abstract available


    July 2020
  6. LAM RPK, Wong KW, Wan CK
    Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
    Lancet. 2020 Jul 13. pii: S0140-6736(20)31560.
    PubMed    


    April 2020
  7. HINKAMP CA, Keshvani N
    Emphasising classification in emphysematous pyelonephritis.
    Lancet. 2020;395:1145.
    PubMed    


    February 2020
  8. PETERS MC, Wenzel SE
    Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
    Lancet. 2020;395:371-383.
    PubMed     Abstract available


    December 2019
  9. BURNEY P, Amaral AFS
    Air pollution and chronic airway disease: is the evidence always clear?
    Lancet. 2019;394:2198-2200.
    PubMed    


    November 2019
  10. BACHERT C, Han JK, Desrosiers M, Hellings PW, et al
    Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Lancet. 2019;394:1638-1650.
    PubMed     Abstract available


    September 2019
  11. FITZGERALD JM, Sadatsafavi M
    Triple therapy in a single inhaler: a new option for uncontrolled asthma.
    Lancet. 2019 Sep 30. pii: S0140-6736(19)32216.
    PubMed    


  12. VIRCHOW JC, Kuna P, Paggiaro P, Papi A, et al
    Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Lancet. 2019 Sep 30. pii: S0140-6736(19)32215.
    PubMed     Abstract available


  13. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available


    August 2019
  14. GAUTHIER M, Wenzel SE
    As-needed beta agonist-inhaled corticosteroid in mild asthma.
    Lancet. 2019 Aug 23. pii: S0140-6736(19)31994.
    PubMed    


  15. HARDY J, Baggott C, Fingleton J, Reddel HK, et al
    Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
    Lancet. 2019 Aug 23. pii: S0140-6736(19)31948.
    PubMed     Abstract available


    June 2019
  16. HUANG K, Yang T, Xu J, Yang L, et al
    Prevalence, risk factors, and management of asthma in China: a national cross-sectional study.
    Lancet. 2019 Jun 20. pii: S0140-6736(19)31147.
    PubMed     Abstract available


  17. BRUSSELLE GG, Ko FW
    Prevalence and burden of asthma in China: time to act.
    Lancet. 2019 Jun 20. pii: S0140-6736(19)31349.
    PubMed    


    May 2019
  18. FLUME PA, Chalmers JD, Olivier KN
    Rheumatoid arthritis-associated bronchiectasis - Authors' reply.
    Lancet. 2019;393:2036.
    PubMed    


  19. PUECHAL X, Bienvenu T, Dusser D
    Rheumatoid arthritis-associated bronchiectasis.
    Lancet. 2019;393:2035-2036.
    PubMed    


  20. DRANSFIELD M, Stolz D, Kleinert S
    Towards eradication of chronic obstructive pulmonary disease: a Lancet Commission.
    Lancet. 2019;393:1786-1788.
    PubMed    


    March 2019
  21. THE LANCET
    Health and wellbeing in adolescence and early adulthood.
    Lancet. 2019;393:847.
    PubMed    


    September 2018
  22. PAPI A, Singh D, Petruzzelli S, Guasconi A, et al
    Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.
    Lancet. 2018;392:1113-1114.
    PubMed    


  23. MARCHAND E
    Inhaled triple therapy in chronic obstructive pulmonary disease.
    Lancet. 2018;392:1112.
    PubMed    


  24. LIPWORTH B, Kuo CR, Jabbal S
    Inhaled triple therapy in chronic obstructive pulmonary disease.
    Lancet. 2018;392:1112-1113.
    PubMed    


  25. MOLIMARD M, Girodet PO, Moore N
    Inhaled triple therapy in chronic obstructive pulmonary disease.
    Lancet. 2018;392:1112.
    PubMed    


  26. VALENZUELA PL, Santos-Lozano A, Morales JS, Drobnic F, et al
    Free to breathe hard in the Tour de France.
    Lancet. 2018;392:1114-1115.
    PubMed    


  27. ZAR HJ, Nicol MP
    Treatment of bronchiectasis exacerbations in children: which antibiotic?
    Lancet. 2018 Sep 17. pii: S0140-6736(18)32004.
    PubMed    


  28. GOYAL V, Grimwood K, Byrnes CA, Morris PS, et al
    Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.
    Lancet. 2018 Sep 17. pii: S0140-6736(18)31723.
    PubMed     Abstract available


  29. FLUME PA, Chalmers JD, Olivier KN
    Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
    Lancet. 2018;392:880-890.
    PubMed     Abstract available


  30. CHANG AB, Bush A, Grimwood K
    Bronchiectasis in children: diagnosis and treatment.
    Lancet. 2018;392:866-879.
    PubMed     Abstract available


    April 2018
  31. VESTBO J, Mathioudakis AG
    The emerging Chinese COPD epidemic.
    Lancet. 2018;391:1642-1643.
    PubMed    


  32. WANG C, Xu J, Yang L, Xu Y, et al
    Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study.
    Lancet. 2018;391:1706-1717.
    PubMed     Abstract available


  33. THE LANCET
    UK COPD treatment: failing to progress.
    Lancet. 2018;391:1550.
    PubMed    


    March 2018
  34. AGUSTI A
    Filling the gaps in COPD: the TRIBUTE study.
    Lancet. 2018;391:1004-1006.
    PubMed    


  35. PAPI A, Vestbo J, Fabbri L, Corradi M, et al
    Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Lancet. 2018;391:1076-1084.
    PubMed     Abstract available


    February 2018
  36. THE LANCET
    Asthma in US children.
    Lancet. 2018;391:632.
    PubMed    


    January 2018
  37. MOSLER G, Euba T
    Taking control through drama.
    Lancet. 2018;391:303-304.
    PubMed    


  38. WATTS G
    Ian Pavord: engaging with the eosinophil.
    Lancet. 2018;391:301.
    PubMed    


  39. CROOKS MG, Faruqi S, Morice AH
    How does azithromycin improve asthma exacerbations?
    Lancet. 2018;391:28.
    PubMed    


  40. GIBSON PG
    How does azithromycin improve asthma exacerbations? - Author's reply.
    Lancet. 2018;391:28-29.
    PubMed    


    December 2017
  41. PAPI A, Brightling C, Pedersen SE, Reddel HK, et al
    Asthma.
    Lancet. 2017 Dec 19. pii: S0140-6736(17)33311.
    PubMed     Abstract available


  42. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Abstract available


    September 2017
  43. DAVIES P, Bradley C
    Vanishing lung syndrome: giant bullous emphysema.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32246.
    PubMed    


  44. PAVORD ID, Beasley R, Agusti A, Anderson GP, et al
    After asthma: redefining airways diseases.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)30879.
    PubMed    


  45. KLEINERT S, Horton R
    After asthma: airways diseases need a new name and a revolution.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32205.
    PubMed    


  46. CAMARGO CA JR
    Transformational thinking about asthma.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32126.
    PubMed    


  47. WOODCOCK A, Vestbo J, Bakerly ND, New J, et al
    Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32397.
    PubMed     Abstract available


  48. GIBSON P
    Effectiveness trials in asthma: time to SaLSA?
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32398.
    PubMed    


    February 2017
  49. THE LANCET
    Complexities of care in COPD.
    Lancet. 2017;389:574.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: